ALX Oncology Holdings Inc. ALXO

Full chart Compare
Set alert

Price alert · ALXO

All alert types
1.33 USD +0.04 (+3.10%)

Nov 4, 2026, 11:24 AM EST

1.32 Day range 1.40
0.862 52-week range 2.66
YTD
+17.70%
1 year
-8.90%
Market cap
183.91M
EPS (ttm)
-1.13
Shares out
52.74M
Forward P/E
-0.68
YTD return
+17.70%
1-year return
-8.90%
Volume
270.60K
Avg volume
1.29M
Open
1.32
Previous close
1.29
Day's range
1.32 – 1.40
52-week range
0.862 – 2.66
Beta
1.04
Analysts
Buy
Price target
7.67 (+476.4%)
Earnings date
Aug 8, 2024

5D +0.24 (+22.43%)

11.201.40WedThuFriMon1.31

Key statistics

Enterprise value
-45.77M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.71
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-74.55M
Total cash
148.57M
Total debt
17.36M
Return on equity
-98.94%
Short % of float
23.56%
50-day average
1.50
200-day average
6.33

Financials — quick view

All financials
ALXO Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALXO Net income — quarterly -17.97M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALXO EPS — quarterly -0.13
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ALXO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.78-0.58+0.20+25.64%
Aug 8, 2024Jun 1, 2024-0.77-0.76+0.01+1.30%
Aug 8, 2024Jun 1, 2024-0.77———
May 9, 2024Mar 1, 2024-0.87-0.71+0.16+18.39%
May 9, 2024Mar 1, 2024-0.87———
Mar 7, 2024Dec 1, 2023-0.84———

Upgrades / downgrades

ALXO analyst upgrades and downgrades
DateFirmActionFromTo
Dec 19, 2024JefferiesdownBuyHold
Dec 18, 2024Cantor FitzgeraldreitOverweightOverweight
Dec 18, 2024HC Wainwright & Co.reitBuyBuy
Nov 12, 2024Cantor Fitzgeraldreit—Overweight
Aug 16, 2024UBSmainBuyBuy
Aug 13, 2024HC Wainwright & Co.reitBuyBuy

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ALXO — it syncs with the Stock Master app.

Insider holders

ALXO insider holders
InsiderRelationLatest transactionDateShares held
GARCIA PETER SChief Financial OfficerPurchaseJun 12, 2024122,348
HEMRAJANI REKHADirectorPurchaseDec 1, 202433,000
LETTMANN JASONChief Executive OfficerPurchaseMar 13, 2024171,620
PINTO SHELLYOfficerSaleAug 13, 202491,549
PONS JAUMEPresidentSaleAug 13, 2024591,510
RANDOLPH SOPHIAOfficerSaleAug 13, 2024325,711

Institution ownership

ALXO institution ownership
Holder% heldSharesValueReported
venBio Partners LLC18.39%9,699,92517.75MSep 29, 2024
FMR, LLC11.12%5,865,10610.73MSep 29, 2024
Tang Capital Management, LLC7.97%4,204,7357.69MSep 29, 2024
Vivo Capital, LLC7.65%4,034,5227.38MSep 29, 2024
Redmile Group, LLC7.27%3,836,5767.02MSep 29, 2024
Blackrock Inc.4.93%2,601,7764.76MSep 29, 2024

Fund ownership

ALXO fund ownership
Holder% heldSharesValueReported
Fidelity Small Cap Growth Fund3.20%1,689,6203.09MAug 30, 2024
Fidelity Series Small Cap Opportunities Fund2.00%1,057,2201.93MAug 30, 2024
Vanguard Total Stock Market Index Fund1.87%984,5861.80MSep 29, 2024
iShares Russell 2000 ETF1.64%867,1991.59MOct 30, 2024
Fidelity Select Portfolios - Biotechnology1.58%835,5041.53MOct 30, 2024
Fidelity Small Cap Growth K6 Fund1.18%621,4971.14MAug 30, 2024